Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Savara Inc. (SVRA) received an amended Schedule 13G from Nantahala Capital Management and its principals, Wilmot B. Harkey and Daniel Mack, reporting their beneficial ownership in the company’s common stock. As of December 31, 2025, they may be deemed to beneficially own 7,344,783 shares, representing 3.61% of Savara’s outstanding common stock.
The filing shows they have no sole voting or dispositive power, but share voting and dispositive power over all reported shares through funds and accounts managed by Nantahala. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Savara.
Savara Inc. received an updated Schedule 13G/A (Amendment No. 10) from a group of Farallon-managed investment funds reporting their beneficial ownership in the company’s common stock. The Farallon funds collectively hold 15,000,000 Common Stock Purchase Warrants, each currently exercisable to buy one Savara share.
Because the warrants contain a 9.99% Beneficial Ownership Limitation, Farallon reports beneficial ownership of 6.9% of Savara’s common stock, based on assuming all 15,000,000 warrants are exercisable within 60 days. The amendment also updates the listed individual reporting persons, adding Avner A. Husen and removing Richard B. Fried, Rajiv A. Patel, and William Seybold as of year-end 2025.
Savara Inc. entered into a First Amendment to its Loan and Security Agreement with Hercules Capital and other lenders. As amended, the agreement allows the company to borrow up to an aggregate of $105 million in term loans. The amendment resets the timing and conditions for Savara to draw up to $75 million of additional term loans, which become available only if the FDA approves its MOLBREEVI product candidate for treating aPAP. It also pushes back the initial dates for certain cash and revenue financial covenants to April 1, 2027 and September 30, 2027 if Savara’s market capitalization falls below specified thresholds, and grants lenders a first‑priority security interest in the company’s intellectual property, which can revert to a negative pledge if a related purchase agreement is terminated and unrestricted cash remains at or above $50 million.
BlackRock, Inc. has disclosed a significant ownership stake in Savara Inc. common stock on a Schedule 13G. BlackRock reports beneficial ownership of 10,957,322 shares of Savara common stock, representing 5.4% of the outstanding class as of the event date 12/31/2025. BlackRock has sole voting power over 10,820,963 shares and sole dispositive power over 10,957,322 shares, with no shared voting or dispositive power.
The filing states that these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Savara. Various underlying clients and investors have the right to receive dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Savara Inc. has furnished an updated corporate presentation for investors. The presentation is available on the company’s Investor Relations website and has also been provided as Exhibit 99.1 to a current report. Savara states it has no duty to update or revise the presentation, although it may choose to do so through its website, future SEC reports, press releases, or other public disclosures. The information in this investor presentation is expressly treated as furnished rather than filed under securities laws and is not automatically incorporated into other SEC filings unless specifically referenced.
Savara Inc's Chief Financial Officer, David Lowrance, reported two transactions in the company’s common stock. On December 14, 2025, 62,960 shares were disposed of at $6.92 per share, representing shares withheld by Savara to cover tax liabilities from the vesting of previously awarded restricted stock units, leaving him with 318,045 shares owned directly.
On December 16, 2025, he reported a bona fide gift of 32,000 shares to The McCallie School at a reported price of $0.00 per share, after which he directly owned 286,045 shares of Savara common stock. He does not have voting or investment power over the shares held by The McCallie School.
Savara Inc director and chief executive officer Matthew Pauls reported two changes in his common stock holdings. On 12/14/2025, 195,705 shares of common stock were disposed of at $6.92 per share, representing shares withheld by the company to cover tax liabilities arising from the vesting of previously awarded restricted stock units. After this, he held 1,317,045 shares.
On 12/16/2025, he reported a disposition of 128,995 common shares at a price of $0.00, reflecting a transfer to the GP 2024 Trust, U/A dated 12/20/2024, for no consideration. He is not a trustee of the trust and does not retain investment or voting control over those shares, and disclaims beneficial ownership except to the extent of any pecuniary interest. Following this gift, he beneficially owns 1,188,050 Savara common shares directly.
Savara Inc reported an insider equity transaction by its Chief Operating Officer, Robert Lutz. On 12/14/2025, the company withheld 67,760 shares of Savara common stock at $6.92 per share to cover his tax obligations arising from the vesting of previously awarded restricted stock units.
After this tax-related share withholding, Robert Lutz directly beneficially owned 293,977 shares of Savara common stock.
Savara Inc's chief legal officer reported an equity transaction involving company stock. On 12/14/2025, Savara withheld 39,350 shares of common stock at $6.92 per share to satisfy the reporting person's tax liability arising from the vesting of previously awarded restricted stock units. After this tax withholding transaction, the officer beneficially owned 519,232 shares of Savara common stock directly.
Savara Inc chief business officer Anne Erickson reported a tax-related disposition of common stock. On 12/14/2025, 62,960 shares of Savara common stock were withheld by the company at a price of $6.92 per share to satisfy her tax liability upon vesting of previously awarded restricted stock units. After this withholding transaction, she directly beneficially owns 371,712 Savara shares.